To read the full story
Related Article
- Yescarta, Breyanzi Clear Panel Review for Second-Line Use
December 13, 2022
BUSINESS
- JRI Urges Reforms in Pricing and Reimbursement to Support Regenerative Medicine Ecosystem
July 18, 2025
- Astellas Partners with KISED to Support Korean Biotech Startups
July 18, 2025
- Kowa Picks Up Global Rights to Nicox’s Glaucoma Drug Excluding Asia
July 18, 2025
- Alnylam’s Amvuttra Could Become First-Line Therapy for ATTR-CM, Says Expert
July 18, 2025
- Otsuka Taps Autoimmune Diseases as Strategic Pillar for Long-Term Growth
July 17, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…